P-113 Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma | Openshaw M, et al | Annals of Oncology | Jun. 2023

Openshaw M, Hastings R, Jamal-Hanjani M, Swanton C, Shaw J, et al. P-113 Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma. Annals of Oncology. 2023;34:S54.

Nonacus product: Oncology

Abstract

Oesophageal adenocarcinoma (OA) has a dismal survival rate and no routine blood-borne biomarker. Circulating tumour DNA (ctDNA) detection in plasma DNA is an emerging non-invasive biomarker. OA ctDNA analysis has previously been shown to track disease relapse and progression. However, little is known about how well ctDNA reflects genetic tumour evolution over time. Two patients with OA that had previously undergone tumour sampling at diagnosis and longitudinal plasma DNA collection were recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) study. Providing a unique opportunity to compare tumour- and ct-DNA from diagnosis to death.